| Trial ID # | NCT05918445 |
| Phase | I/II |
| Drug Class | Immunotherapy: Bispecifics/PD-L1, VEGF |
| Drug Name | BNT327 |
| Alternate Drug Names | anti-PD-L1/anti-VEGF-A bispecific antibody PM8002, PM8002 |
| Drugs in Trial | BNT327 |
| Eligible Participant | Platinum resistant ovarian cancer (0-1 prior therapies for platinum resistant recurrence) |
| Patients Enrolled | 39 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, PFS, OS, evaluated per RECIST |
| Efficacy | ORR: 20.6% (7PR, n=34) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | BNT327 (PM8002) shows promising anti-tumor activity in previously treated patients with Pt-R OC |
| Reference | Wu L et al. Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts. J Clin Oncol 42, 2024 (suppl 16; abstr 5524) Wu L et al. Poster |